How Will the EU JCA Reshape National HTA Across Europe, Dr. Oriol Solà-Morales?
From MAP - Market Access Podcast · 39:36
Show by Dr. Stefan Walzer
Is the EU Joint Clinical Assessment just another administrative layer, or the start of a truly European HTA? In this MAP episode, Dr. Stefan Walzer talks with Dr. Oriol Solà-Morales, physician, health economist, founder and CEO of HITT and founding member of EUnetHTA, about what the first JCA reports reveal.Drawing on Spain's shift from regional to coordinated HTA, Oriol sees the JCA's potential to build Europe. He describes a deliberately conservative start: concise PICO consolidation, uncertainties named but not resolved, and a clear line between the European assessment and national reimbursement decisions. They discuss how countries like Germany may gradually adapt, for example on indirect comparisons and progression-free survival, and why JCA requirements belong in development planning by the end of phase I. Success, in his view, means more transparency and a stable, predictable environment for development in Europe.Connect with Oriol on LinkedIn:https://www.linkedin.com/in/oriol-sol%C3%A0-morales-a130692/Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts — and if you enjoyed the episode, don't forget to rate it and the podcast!MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/#MarketAccess #HealthEconomics #Pharma #PricingStrategy #MAPPodcast #HTA #JCA #EUHTA #HTARegulation #Reimbursement #DrugDevelopment
More episodes of MAP - Market Access Podcast
More episodes
- How Can HEOR Teams Build Trust in AI-Generated Models, Haidong Feng?
- Can US GLOBE and GUARD Models Really Lower Drug Prices, Brittany La Couture?
- What Will It Take to Keep Biotech Growing in Europe, Rainer Westermann?
- How Do You Build a High-Performing Team in Pharma, Dr. Maurice Kléber?
- Dr. Mathias Flume - AMNOG will change in 2022, but how?
- Prof. Dr. Wagschal - What can we expect from the upcoming elections in Germany?
- Remo Christen – Early paid access in Switzerland – Switzerland, wonderland??
- Prof. Dr. David Matusiewicz & Dr. Anne Sophie Geier - 1 year DIGAs. Is the "fast track process" for digital health applications successful?
- Bibiane Schulte-Bosse - How to fight well in AMNOG negotiations.
- Prof. Peter Zweifel & Door Vonk - Digital innovation - from theory into practice!
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.